<DOC>
	<DOCNO>NCT00443170</DOCNO>
	<brief_summary>This first time human study investigate safety GSK626616AC give oral single repeat dose healthy subject . An additional group subject assess determine effect several drug give time GSK626616 .</brief_summary>
	<brief_title>A Placebo-controlled Study Investigate Safety , Pharmacokinetics Oral GSK626616AC Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Flurbiprofen</mesh_term>
	<mesh_term>Caffeine</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Age 18 55 year healthy subject Hemoglobin value 13.517.0 g/dL male 12.015.5 g/dL female . Females pregnant . Can exposure great 4 new chemical entity within 12 month . Can clinical history current alcohol , illicit drug use , judgment Investigator , would interfere subject 's ability comply dose schedule . Can history regular use tobacco nicotinecontaining product within 3 month . Must receive blood transfusion donation blood within 3 month prior study entry . Can use take prescription , nonprescription illicit drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>repeat dose ,</keyword>
	<keyword>GSK626616AC ,</keyword>
	<keyword>pharmacokinetic ,</keyword>
	<keyword>single dose ,</keyword>
	<keyword>cytochrome P450 ,</keyword>
	<keyword>First time human ,</keyword>
	<keyword>healthy volunteer</keyword>
</DOC>